Defensividad

Ajwain has clinically documented bronchodilatory effects in asthmatic patients (Boskabady 2007) and preclinical antitussive data (Boskabady 2005). Combined with antimicrobial activity against respiratory pathogens, it has scientifically characterized activity across multiple aspects of upper and lower respiratory health.

Andrographis paniculata has robust clinical evidence for URTI treatment. A DARE-assessed systematic review of 7 controlled trials (n=896) found it significantly superior to placebo for uncomplicated URTI symptom relief. A double-blind RCT of KalmCold (200 mg/day, n=223) showed significant improvement in all nine measured URTI symptoms by day 5 vs. placebo.

Andrographolide is the principal diterpene lactone from Andrographis paniculata responsible for anti-URTI activity. It inhibits NF-κB-mediated inflammation, modulates immune responses, and has demonstrated antiviral activity against influenza and RSV. Clinical RCTs using andrographolide-standardized extracts show significant URTI symptom improvement.

Clinical evidence, including a 199-person RCT over 12 weeks, demonstrates that larch arabinogalactan supplementation significantly reduced the incidence and number of participants affected by upper respiratory tract infections. Additional vaccine-response studies further support an immunostimulatory effect relevant to upper respiratory defence. Mechanistic data suggest NK cell enhancement and macrophage activation as contributing pathways.

A randomized, double-blind, placebo-controlled trial in 61 adults prone to upper respiratory tract infections found that a blend containing Aronia melanocarpa significantly reduced URTI incidence over a 60-day period. In vitro studies confirm that Aronia juice inhibits influenza virus replication, including drug-resistant strains.

A pilot RCT in 80 children showed B. clausii significantly reduced both the number and duration of recurrent respiratory infections over a treatment and follow-up period. The gut-lung immune axis is proposed as the mechanism. Evidence is currently limited to small pilot studies, and larger confirmatory trials are needed.

Beta-glucans from yeast or mushrooms have clinical evidence from multiple RCTs for reducing URTI incidence, severity, and duration through activation of innate immune cells (macrophages, neutrophils) via Dectin-1 and complement receptors. Multiple trials in stressed populations show consistent reductions in cold frequency and sick days.

Clinical studies show that B. animalis subsp. lactis BB-12, often combined with L. rhamnosus GG, reduces the duration and severity of upper respiratory tract infections (URTI) in healthy adults and college students. A crossover RCT found participants receiving BB-12 had elevated NK-cell cytotoxicity and IL-2 secretion concurrently with fewer URTI days. BB-12 has also been linked to increased body resistance to common respiratory infections across multiple clinical studies.

Multiple clinical trials, including a large RCT with B. lactis Bl-04 and combination trials with B. lactis BB-12 and HN019, demonstrate that B. lactis supplementation reduces the risk, duration, or severity of upper respiratory tract infections. Effects are linked to enhanced NK-cell function, secretory IgA, and mucosal immunity.

Bromelain has been evaluated in clinical studies for chronic sinusitis and upper respiratory tract infections, demonstrating immunomodulatory, mucolytic, and anti-inflammatory effects on nasal mucosa. A case-control study found that adding a bromelain-containing supplement to standard sinusitis treatment improved nasal hyperemia, rhinorrhea, and inflammatory markers (WBC, IgE, CRP). It is used clinically in Europe as part of combination products for sinusitis.

The PMC 2023 bibliometric review found clinical evidence for camphor/menthol compounds in upper respiratory infection symptom management, including cough suppression and congestion relief. Camphor is a recognized OTC ingredient in chest rubs and nasal decongestant products. The mechanism involves TRP channel modulation inhibiting respiratory reflexes.

Cod liver oil's vitamin D reduces susceptibility to respiratory tract infections by supporting innate and adaptive mucosal immunity. An observational study (HUNT study, Norway) found regular cod liver oil intake was associated with lower incidence of adult asthma. CLO's anti-inflammatory properties also modulate airway inflammation.

Bovine colostrum supplementation significantly reduces the incidence and duration of upper respiratory tract infections (URTIs). A 2016 meta-analysis of five RCTs found a 44% reduction in symptomatic URTI days and a 38% reduction in URTI episodes. Benefits extend beyond athletes to higher-risk non-athletic populations.

Multiple systematic reviews and meta-analyses have evaluated Echinacea for upper respiratory tract infections. A 2019 meta-analysis found a risk ratio of 0.78 (95% CI 0.68–0.88) for URTI prevention. Evidence suggests modest benefit for early treatment and possible prevention of acute URIs. A Cochrane review (2014) also found some preparations reduced cold incidence and duration.

Echinacea purpurea is the most clinically studied Echinacea species for URTI. Randomized controlled trials demonstrate it reduces severity and duration of cold symptoms. A 2025 meta-analysis of 9 RCTs in children confirmed its efficacy for URTI treatment and prevention of otitis media complications.

EGCG is the primary catechin in green tea responsible for antiviral activity against influenza, RSV, and other respiratory viruses. Green tea EGCG supplementation significantly reduced laboratory-confirmed influenza infections in a double-blind RCT of healthcare workers (n=197, OR 0.27). It inhibits viral neuraminidase, hemagglutinin, and RNA polymerase.

Black elderberry (Sambucus nigra) has clinical evidence from multiple RCTs and a 2019 meta-analysis (4 studies) finding significant reductions in upper respiratory symptom duration and severity vs. placebo. A Cochrane-methodology 2021 systematic review of 5 RCTs found elderberry may reduce cold and influenza duration, though evidence certainty is rated as low-to-uncertain.

Eucalyptus oil (1,8-cineole/eucalyptol) has Commission E and EMA approval for catarrhs of the upper respiratory tract. Clinical RCTs found oral cineole (200 mg 3×/day) significantly improved acute non-purulent sinusitis and bronchitis severity vs. placebo. It acts as a secretolytic, bronchospasmolytic, and antimicrobial agent.

Elderberry is one of the most clinically studied botanicals for upper respiratory viral infections. RCT and meta-analytic evidence support reductions in duration and severity of upper respiratory symptoms. The EMA and German Commission E both recognize elderflower preparations for upper respiratory conditions. Evidence is stronger for influenza than for common cold.

Fritillary is pharmacologically active against multiple mechanisms relevant to upper respiratory disease: antitussive, expectorant, antibacterial, and anti-inflammatory. It is used clinically in TCM for upper respiratory infections. Preclinical studies demonstrate inhibition of respiratory epithelial mucin production and reduction of inflammatory cytokines.

Garlic allicin has demonstrated in vitro antibacterial activity against major lung pathogens including Streptococcus pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus, including MDR strains. Traditional use across Chinese, Japanese, and North American indigenous cultures for respiratory conditions is also documented. Clinical RCT evidence for upper respiratory tract infections beyond the common cold is limited.

Pelargonium sidoides has robust clinical evidence for upper respiratory tract infections including cold, bronchitis, and sinusitis, backed by a Cochrane review and EMA regulatory approval. P. graveolens shows ethnobotanical and in vitro evidence for respiratory use including viral ACE2 inhibition.

North American ginseng (Panax quinquefolius, COLD-FX) has clinical evidence from double-blind RCTs showing significant reduction in cold incidence in elderly adults (10% vs. 22.8% in placebo, p=0.002). NCCIH cites inconsistent but supportive evidence for both Asian and North American ginseng for URTI prevention.

Ginsenosides are the primary bioactive saponins of Panax ginseng and P. quinquefolius responsible for immunomodulatory effects relevant to URTI prevention. They enhance NK cell activity, T-cell proliferation, and interferon production. Clinical URTI evidence is primarily from COLD-FX (standardized North American ginseng) RCTs showing significant cold incidence reduction.

Green chiretta has the most robust clinical evidence of any botanical for acute upper respiratory tract infections (URTIs). A mechanistic systematic review confirms immunomodulation, antiviral activity, and antipyretic effects underpinning this action. Both monotherapy and combination products reduce URTI symptom severity and duration in RCTs.

Green tea catechins (primarily EGCG) have clinical evidence for reducing influenza and URTI incidence. A double-blind RCT (n=197 healthcare workers) found green tea catechin supplementation significantly reduced laboratory-confirmed influenza infection rates. EGCG inhibits influenza viral neuraminidase and hemagglutinin in preclinical studies.

Honey has clinical RCT evidence for nocturnal cough in children with upper respiratory infections. A landmark 2007 RCT (n=105 children) found buckwheat honey significantly outperformed dextromethorphan and no treatment for URTI-related cough. WHO and multiple guidelines recognize honey as a low-cost option for childhood cough associated with URTI.

Multiple clinical studies have investigated a fixed combination of horseradish root and nasturtium (Angocin Anti-Infekt N) for acute sinusitis and bronchitis. A prospective cohort study in 1,649 adults found symptom reduction comparable to standard antibiotics for sinusitis and bronchitis, with fewer side effects. A randomised, double-blind, placebo-controlled phase IV trial further supported the product's efficacy for acute bronchitis. Evidence is for the combination product, not isolated horseradish.

L. casei Shirota has been evaluated in RCTs for reducing the incidence and duration of upper respiratory tract infections (URTIs) in adults and children. A published RCT in healthy middle-aged office workers found that daily fermented milk with L. casei Shirota reduced URTI incidence and duration. A multi-strain formulation including L. casei 431 reduced URTI incidence in susceptible adults via increased IFN-γ and sIgA.

L. paracasei strains have been studied in RCTs for upper respiratory tract infections (URTIs), including a study showing reduced URTI duration in elderly consuming L. paracasei N1115-supplemented yogurt, and the L. casei 431 RCT measuring upper respiratory symptom incidence and duration in 1,104 adults around influenza vaccination.

A 571-child double-blind RCT found LGG supplementation produced a 17% relative reduction in respiratory infections with complications and lower respiratory tract infections. L. rhamnosus D3189 reduced RSV shedding and modulated innate immune responses in nasal epithelial cells in vitro. A patent-protected RCT demonstrated fewer illness days and lower severity scores in the probiotic group versus placebo for upper respiratory tract infections.

Clinical and mechanistic evidence supports L. salivarius benefits for upper respiratory tract health, primarily through immune modulation and competitive exclusion of pathogens. L. salivarius PS7 has been developed specifically for prevention of recurrent acute otitis media and upper respiratory infections in children, with patent-documented clinical reduction in AOM episodes. Small-scale human trials suggest reduced incidence and duration of upper respiratory infections, especially in children and elderly.

A systematic review and meta-analysis of 25 human studies found that lactoferrin supplementation improved immune function and reduced systemic inflammation in the majority of trials, with several studies specifically addressing respiratory tract infection (RTI) outcomes. Evidence is strongest for reducing RTI incidence in select populations.

Lactoperoxidase is secreted by airway mucosal glands into the respiratory surface liquid, where it forms part of the innate antimicrobial defense of the airways. The LPO/thiocyanate/H₂O₂ system in tracheal and bronchial epithelial cells has been shown to produce hypothiocyanite that inactivates respiratory bacteria and viruses. Evidence is from ex vivo and cell/tissue studies; there are no clinical intervention trials with exogenous LPO for upper respiratory conditions.

Two published randomized clinical trials tested a combination product (KanJang) containing Adhatoda vasica leaf extract in patients with acute upper respiratory tract infections, showing significant improvement in coughing, mucus clearance, and nasal congestion. One trial was double-blind placebo-controlled; both are published in Phytomedicine.

Menthol is clinically documented to improve subjective airflow sensation in nasal congestion and to reduce cough reflex via TRPM8 receptor activation. It is a recognized active ingredient in products approved for upper respiratory tract symptomatic relief.

Monolaurin demonstrates in vitro activity against multiple enveloped respiratory viruses (influenza, coronaviruses, RSV). An unpublished safety study found nasal administration of 5% GML gel to 50 individuals produced no adverse effects, and prior macaque research showed nasal GML prevented SIV transmission. No completed human RCTs for upper respiratory infections exist.

N-Acetyl Cysteine (NAC) is approved in multiple countries as a mucolytic for respiratory conditions. It reduces mucus viscosity, has antiviral activity against influenza and RSV, and is recommended as supportive therapy for upper respiratory infections including chronic rhinosinusitis. A 2015 Cochrane review confirmed NAC reduces exacerbation rates in chronic bronchitis.

Onion and its bioactive constituents (quercetin, thiosulfinates, sulfur compounds) have documented effects on upper respiratory health, including bronchial relaxation, anti-inflammatory, and antimicrobial activity relevant to upper respiratory tract conditions. The 2021 PMC comprehensive review confirmed evidence across respiratory and immunological endpoints for A. cepa.

Pelargonium sidoides root extract (EPs 7630/Umckaloabo) has Cochrane-reviewed clinical evidence for acute respiratory tract infections. Multiple RCTs found it effective for bronchitis, sinusitis, tonsillopharyngitis, and the common cold. It has been approved for acute bronchitis treatment in Germany since 2005.

P. integerrima galls are among the most studied plants for respiratory conditions. Preclinical studies confirm bronchodilatory, mast-cell stabilizing, antihistaminic, and anti-inflammatory effects relevant to upper and lower respiratory health. Clinical observations in poly-herbal formulations report improvement in respiratory rate and prevention of respiratory attacks. The Springer 3 Biotech 2026 review provides the most up-to-date synthesis.

Plantago lanceolata is endorsed by the German Commission E and ESCOP for catarrh of the upper airways and inflammation of oral and pharyngeal mucosa. Clinical studies demonstrate anti-inflammatory, spasmolytic, and immunostimulant activity relevant to upper respiratory infections. ESCOP's open clinical study confirms efficacy in respiratory catarrh.

Plantago lanceolata is officially used and pharmacopoeially recognized for upper respiratory tract infections including cough and pharyngeal inflammation. P. major extracts show anti-inflammatory, spasmolytic, and antimicrobial activity in the upper airways. Human trials and monograph-level recognition support this application.

In vitro studies show that secoiridoid constituents of Ligustrum lucidum, including oleuropein and ligulucisides, inhibit respiratory syncytial virus (RSV), parainfluenza type 3, and influenza A virus. Traditional use also includes treatment of respiratory tract infections. No human trials exist.

Quercetin has antiviral activity against influenza, RSV, and rhinoviruses in preclinical studies, and a double-blind RCT in athletes (n=40) found significant reduction in URTI episodes (1 vs. 9 in placebo). It inhibits viral neuraminidase, NF-κB signaling, and enhances interferon responses relevant to upper respiratory defense.

Rose hips support upper respiratory health primarily through their high vitamin C content, which reduces the severity and duration of upper respiratory infections. Anti-inflammatory flavonoids, including quercetin, may soothe airway mucous membranes and exhibit antihistamine-like properties. Meta-analyses of vitamin C supplementation confirm 8–14% reduction in cold duration, directly applicable to rose hip's principal bioactive.

A published human clinical trial demonstrated that oral rosmarinic acid (50 mg or 200 mg/day for 21 days) significantly reduced symptoms of seasonal allergic rhinoconjunctivitis (SAR), decreased nasal neutrophil and eosinophil counts, and outperformed placebo. RA has also been documented in traditional use for upper respiratory complaints in Lamiaceae herbal medicine.

Serratiopeptidase has demonstrated clinical benefit across multiple upper respiratory conditions including sinusitis, laryngitis, rhinitis, and ENT inflammation in general. The 1990 Mazzone et al. multicenter RCT (n=193) documented significant symptom improvement in acute or chronic ENT pathologies. Clinical use in upper respiratory conditions has been established in Japan and Europe for decades.

Thyme (Thymus vulgaris) has Commission E and EMA approval for symptomatic relief of cough and upper respiratory catarrh. Multiple clinical trials of ivy/thyme combination preparations showed significant improvement in bronchitis severity. Its thymol and carvacrol components provide expectorant, spasmolytic, and antimicrobial actions.

Thymus vulgaris is formally approved by the German Commission E and recognised by the EMA HMPC and ESCOP for catarrh of the upper respiratory tract and productive cough associated with colds. Clinical trial evidence from multiple double-blind RCTs supports thyme-containing preparations for upper respiratory tract infections with productive cough.

Vitamin C has been extensively studied for the common cold via Cochrane meta-analysis. Regular supplementation modestly reduces cold duration (8% in adults, 14% in children) and severity but does not prevent colds in the general population. Populations under heavy physical or cold stress show greater preventive benefit (RR ~0.48).

Vitamin D has robust evidence from a landmark 2017 BMJ meta-analysis (25 RCTs, n=11,321) finding supplementation significantly reduced acute respiratory infection incidence. It induces antimicrobial peptide production (cathelicidin/LL-37) against respiratory pathogens and modulates immune inflammatory responses during URTI.

Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D used in URTI clinical research. The landmark 2017 BMJ meta-analysis (25 RCTs, n=11,321) found D3 supplementation significantly reduced acute respiratory infection incidence, with greatest benefit in severely deficient individuals using daily/weekly dosing.

Zinc lozenges are among the best-evidenced interventions for reducing common cold duration. NCCIH and a 2015 meta-analysis (3 RCTs, 80–92 mg/day zinc acetate) confirm significant reductions in nasal discharge (34%), nasal congestion (37%), cough (46%), and hoarseness (43%). Zinc lozenges should be started within 24 hours of symptom onset.

Mouth and upper respiratory tract disorders are among the documented traditional indications of A. spectabilis in Himalayan ethnobotany. The leaves' expectorant, antimicrobial, and antitussive properties support this application.

Allicin, the principal antimicrobial compound of garlic, was 'highly effective in one small trial' for cold prevention per NCCIH. It demonstrates antimicrobial and antiviral activity against influenza viruses and rhinoviruses in preclinical studies. Clinical evidence is limited to a single RCT requiring replication.

Alliin is the stable sulfur-containing precursor in garlic that enzymatically converts to allicin upon crushing. As the quality marker for allicin-yielding garlic supplements and as the precursor to garlic's antimicrobial active compounds, alliin is relevant to garlic's traditional and clinical use for upper respiratory infections.

Allspice is documented in traditional herbalism for chest infections, respiratory congestion, and coughs. Its volatile oils have expectorant and antimicrobial properties. In vitro research confirms antimicrobial activity against respiratory pathogens. No human trials exist.

In Western folk herbalism and TCM, Aster root has been used for upper respiratory infections, throat irritation, and acute cough with phlegm. TCM texts document use dating back over 2,000 years for clearing lung qi and alleviating acute respiratory symptoms. Scientific evidence supporting upper respiratory efficacy in humans is lacking.

Astragaloside is a key saponin constituent of Astragalus membranaceus responsible for immunomodulatory activity relevant to URTI prevention. It activates T lymphocytes, NK cells, and macrophages, and contributes to astragalus's traditional role as an immune tonic for preventing upper respiratory infections in TCM.

Astragalus (Astragalus membranaceus) is a foundational herb in Traditional Chinese Medicine used for millennia to prevent upper respiratory infections via immunomodulation. Multiple immunological studies show enhanced immunoglobulin production and T-cell restoration. No direct human URTI RCTs have been completed, but it is widely used preventively.

Baicalin, the primary flavonoid from Baikal skullcap (Scutellaria baicalensis), is a component of Shuanghuanglian widely used in Chinese hospitals for URTI. It demonstrates antiviral activity against influenza, RSV, and parainfluenza viruses, and anti-inflammatory activity via NF-κB inhibition.

Baikal skullcap (Scutellaria baicalensis; Huang Qin) is a cornerstone TCM herb for acute URTI with fever and inflammation. Its active compounds (baicalin, baicalein, wogonin) inhibit influenza, RSV, and parainfluenza viruses and suppress pro-inflammatory signaling. It is a key component of Shuanghuanglian used in Chinese hospitals for URTI.

Balloon flower (Platycodon grandiflorum) root is the common English name for the TCM herb Jie Geng, used for cough, phlegm, and sore throat in upper respiratory conditions. Its saponins provide expectorant, anti-inflammatory, and antiviral activity. It features in multiple classical URTI formulas such as Jie Geng Tang and Sang Ju Yin.

Barberry has traditional use for upper respiratory tract conditions including sinusitis, nasal congestion, and bronchitis, attributed to berberine's antimicrobial properties and anti-inflammatory effects on mucous membranes. Multiple herbal references document this use across traditions.

Bayberry was traditionally used for upper respiratory conditions including laryngitis, sore throat, and catarrhal states of the upper airways. It was a key ingredient in composition powder used for these conditions. TCM also documents its use for laryngitis. No clinical evidence exists.

Bee propolis has traditional use and preclinical/clinical evidence for upper respiratory infections. Its polyphenolic constituents (CAPE, galangin, quercetin) demonstrate antimicrobial, antiviral, and anti-inflammatory activity against respiratory pathogens. A 2023 clinical study found it recommended as supportive therapy for chronic URTI including rhinosinusitis.

Black spruce is traditionally used for upper respiratory complaints including colds, sinus congestion, catarrh, and pharyngitis. The British Herbal Pharmacopoeia supports its use for pharyngitis, and aromatherapy sources document its decongestant and antiseptic properties for the upper respiratory tract.

Boneset has a well-documented traditional role in supporting the upper respiratory tract during acute infections, including nasopharyngeal catarrh, colds, coughs, and allergic rhinitis. Herbal Reality's monograph records its use for these conditions as a hot infusion acting via diaphoretic and expectorant mechanisms. A 19th-century medical text confirmed its use for catarrh. No clinical trials for upper respiratory tract conditions specifically have been conducted.

Cajuput oil is deeply embedded in Southeast Asian, Australian Aboriginal, and European traditional medicine as a respiratory remedy, used by steam inhalation and chest application for coughs, colds, bronchitis, and asthma. Its 1,8-cineole content provides pharmacologically documented expectorant, mucolytic, and anti-inflammatory properties relevant to upper respiratory health. Direct cajuput human clinical evidence is absent.

Cayenne pepper has extensive traditional use for cough, bronchitis, sore throat, and respiratory congestion. Capsaicin's irritant properties stimulate mucosal secretions and airway clearing. Clinical evidence for these specific upper respiratory indications is limited, though nasal capsaicin has been evaluated for rhinitis.

Chrysanthemum is a classic TCM herb for the Lung meridian and is used for cough, congestion, and respiratory infections. It is listed in the Pharmacopoeia of the People's Republic of China as connected to the Lung channel. In vitro studies show antibacterial and anti-inflammatory properties relevant to respiratory health.

Clove and eugenol have documented traditional and pharmacological use for upper respiratory tract infections and mucosal inflammation. A PMC review confirms eugenol is included in medications for upper respiratory mucosa inflammation.

Coltsfoot is one of the most historically prominent European and Chinese herbal remedies for upper respiratory tract complaints including cough, hoarseness, laryngitis, nasal congestion, and airway irritation. Its mucilage, expectorant, and antispasmodic properties are widely described. Clinical evidence is absent.

Upper respiratory support—particularly for bronchitis, whooping cough, and cough with excessive mucus—represents elecampane's primary and most consistently documented traditional indication, recorded in the British Herbal Pharmacopoeia, BHP, ancient Greek texts, Ayurveda, and TCM. Evidence is traditional with mechanistic in vitro support but no clinical trials.

Asafoetida is one of the most widely documented traditional remedies for upper and lower respiratory conditions, including bronchitis, asthma, whooping cough, and influenza, across Ayurvedic, Unani, European, and Middle Eastern medicine. Its expectorant mechanism involves elimination of volatile oil through the lungs.

Forsythia suspensa fruit (Lian Qiao) is a principal TCM herb for upper respiratory infections with fever, sore throat, and inflammation. A key component of Shuanghuanglian (used in Chinese hospitals for URTI) and classical Yin Qiao San formula, its active forsythia glycosides show antiviral activity against influenza and RSV.

Garlic (Allium sativum) has been used globally for millennia for respiratory infections. NCCIH cites one small trial where allicin was highly effective for cold prevention. A Cochrane review found insufficient evidence from trials (only one acceptable RCT showed 63% reduction in cold incidence), though preclinical evidence for allicin's antimicrobial and antiviral activity is strong.

Ginger (Zingiber officinale) has millennia of traditional use in TCM, Ayurveda, and global folk medicine for upper respiratory infections, cough, sore throat, and fever. Its gingerols and shogaols provide anti-inflammatory, antiviral, and expectorant activities. Clinical RCT evidence for isolated ginger in URTI is limited, but traditional use is globally consistent.

Goldenrod is a long-established traditional herb for upper respiratory conditions including nasal catarrh, sinusitis, and sore throat. European herbalism specifically identifies Solidago as an anticatarrhal and diaphoretic for upper respiratory tract infections. It was a primary upper respiratory herb in Europe before Echinacea became widely used.

Goldenseal (Hydrastis canadensis) is a traditional North American herb used by Indigenous peoples and 19th-century herbalists for upper respiratory infections. Its active alkaloid berberine demonstrates antimicrobial activity against common respiratory bacterial pathogens and anti-inflammatory properties relevant to URTI. No modern URTI-specific RCTs exist.

The EMA HMPC formally adopted GMT for traditional use in cough associated with cold. Multiple peer-reviewed reviews document its traditional role across the full spectrum of upper respiratory complaints including cough, rhinitis, sore throat, and nasal congestion. Its antimicrobial, expectorant, and anti-inflammatory properties are biologically relevant.

H. spicatum is traditionally used for cough, hiccough, and upper respiratory complaints, classified in Ayurveda as 'Shwasahara' and appearing in classical anti-cough formulations. The rhizome is documented in Ayurvedic classics specifically for 'treatment of cough, hiccough, fever and asthma.' Antimicrobial activity of the essential oil provides indirect support.

Ho wood essential oil has been traditionally used to clear and purify the respiratory tract. Its antimicrobial linalool content provides a plausible mechanism for supporting upper respiratory health. This use is documented in French and European aromatherapy traditions.

Honey loquat syrup (Pi Pa Gao) is a classical Chinese herbal OTC preparation used since the Tang Dynasty for cough, sore throat, and upper respiratory irritation. It combines honey's demulcent properties with loquat leaf's antitussive and expectorant effects. It is among the most widely used OTC herbal cough preparations in China.

Honeysuckle (Lonicera japonica) flower is a foundational TCM herb for acute upper respiratory infections corresponding to wind-heat patterns (fever, sore throat, nasal congestion). Its active compounds including chlorogenic acid have antiviral and anti-inflammatory properties. It is a primary ingredient in widely used URTI formulas including Shuanghuanglian and Yin Qiao San.

Horehound is classified by EMA HMPC and German Commission E as a traditional herbal medicine for relief of cough associated with upper respiratory tract colds. Its expectorant, mucolytic, and mild antispasmodic actions underpin this use. Human clinical trial evidence is absent; the EMA's positive opinion is based on plausibility and documented traditional use for ≥30 years.

Hyssop has one of its oldest and best-documented traditional uses in upper respiratory tract conditions including coughs, chest congestion, bronchitis, and the common cold. It is regarded as an expectorant and antispasmodic in classical European, Persian, and Uyghur herbal medicine. The NIH LiverTox database notes its use for respiratory tract infections.

H. italicum EO is traditionally used as an expectorant, decongestant, and for colds and cough across Mediterranean folk medicine. In vitro antibacterial activity against key upper respiratory pathogens has been demonstrated; no human clinical trials exist.

I. racemosa has broad traditional documentation for upper respiratory conditions including sinusitis, cough, laryngitis, and nasal congestion across Ayurvedic, Chinese, and Himalayan ethnomedicinal traditions. It is classified as anticatarrhal and expectorant in Ayurvedic pharmacopeias, and is indicated for hiccough and breathing difficulty.

Licorice root has Commission E approval for catarrhs of the upper respiratory tract and bronchitis. Used for millennia in TCM, Ayurveda, and European medicine for sore throat, cough, and bronchitis, its active glycyrrhizin has antiviral and anti-inflammatory properties, and it serves as a demulcent and expectorant in respiratory formulas.

Lobelia has extensive documentation as an expectorant, bronchodilator, and respiratory stimulant across Native American, Eclectic, and contemporary herbal traditions. Alpha-lobeline stimulates respiratory chemoreceptors and relaxes bronchial smooth muscle. Despite a plausible pharmacological mechanism, no human clinical trials have validated efficacy for upper respiratory conditions.

Mango leaves and bark are traditionally used in Ayurveda and folk medicine for asthma, bronchitis, cough, and throat infections. Mango leaf tea is documented as a traditional remedy to soothe irritated respiratory passages. The bark is described as having tonic effects on mucous membranes.

Marjoram has a long and consistent tradition of use for upper respiratory complaints including coughs, colds, and respiratory infections across Moroccan, Mediterranean, Indian, and European folk medicine. Its expectorant, antimicrobial, and anti-inflammatory properties underpin this use.

Marshmallow (Althaea officinalis) has European Medicines Agency and Commission E approval for symptomatic treatment of sore throat and associated dry cough, based on well-established traditional use. Its high mucilage content physically coats and soothes inflamed respiratory mucosae. Used in European herbal medicine for over 2000 years for respiratory tract irritation.

Peppermint is approved by the German Commission E for catarrhs of the upper respiratory tract. Menthol's sensory decongestant effect, combined with the herb's anti-inflammatory and antimicrobial properties, supports traditional use for cough, congestion, and general upper respiratory discomfort.

Mullein (Verbascum thapsus) has been used from antiquity across European, North African, and North American Indigenous traditions for cough, bronchitis, sore throat, and other upper respiratory conditions. Its mucilage provides demulcent effects on respiratory mucosae; its saponins act as expectorants. Human RCT evidence is lacking; evidence is traditional with preclinical support.

Mustard's pungent AITC volatiles are traditionally used to support upper respiratory health, acting as a decongestant and mucolytic. The Herbal Reality monograph documents mustard's volatile oils as mucolytic via thinning mucus, and as antimicrobial when excreted through the lungs. These uses span Western folk medicine, Ayurveda, and traditional Chinese medicine.

Myrrh is traditionally used as an expectorant for upper respiratory conditions, including head colds, nasal congestion, bronchial infections, and sore throats. It is documented in multiple traditional systems as an immune stimulant and expectorant during cold and flu season. No dedicated human clinical trials exist.

Oregano is one of the most consistently documented traditional remedies for upper respiratory infections — including colds, flu, and coughs — across Greek, Roman, Chinese, Turkish, and European herbal traditions. Multiple traditional medicine systems document its use as an expectorant and antispasmodic for upper airway conditions. Clinical evidence in humans is lacking but antimicrobial and anti-inflammatory mechanisms provide biological plausibility.

P. orientalis is documented in the Chinese Pharmacopoeia and multiple ancient materia medica texts as an antitussive and expectorant medicine, used for coughs, excessive mucus, bronchitis, and related upper respiratory conditions. This is among the most consistently recorded traditional indications.

Peppermint (Mentha x piperita) leaf and oil have Commission E approval for catarrhs of the upper respiratory tract. Menthol activates TRPM8 receptors to reduce perceived nasal congestion, and has mild anesthetic effects on sore throat. EMA has established a monograph for nasal congestion relief in URTI.

Perilla has been used in TCM for over 2,000 years as a primary herb for upper respiratory complaints including colds, coughs, and nasal congestion due to wind-cold exposure. The herb appears in multiple classical TCM formulae for these indications. Modern pharmacological studies confirm anti-inflammatory and anti-microbial properties supportive of this traditional use.

P. kurroa is classically used in Ayurvedic and Tibetan medicine for upper respiratory conditions including colds, coughs, and sore throat. Traditional practitioners in Tibet, Nepal, and India widely recommend it for these complaints, and it is a listed traditional use in multiple ethnopharmacological reviews.

Pine has been used traditionally across many cultures (Native American, ancient Greek, medieval European, Chinese) for upper respiratory conditions. Pine resin, bark tea, and needle steam preparations were used for coughs, colds, bronchitis, and upper respiratory infections. Modern pine extracts appear in cough syrups and lozenges.

Platycodon grandiflorum (balloon flower) root is used in TCM and Korean traditional medicine for cough, sore throat, and phlegm in upper respiratory conditions. Its triterpenoid saponins (platycodin D) have expectorant, anti-inflammatory, and antiviral properties. It appears in multiple classical URTI formulas.

Platycodon root (Platycodon grandiflorum; Jie Geng) is a primary TCM expectorant herb used for cough, sore throat, and phlegm associated with upper respiratory infections. Its triterpenoid saponins (platycodin D) provide expectorant, anti-inflammatory, and antiviral activity. It is a component of multiple classical URTI formulas including Sang Ju Yin.

Polygala root has traditional use in TCM for upper respiratory complaints including colds, cough, and phlegm congestion. It was traditionally used 'for colds and mild respiratory problems' and is listed in the Chinese Pharmacopoeia as an expectorant targeting the Lung meridian.

Bee propolis has traditional use across Mediterranean and Eastern European folk medicine for throat infections and upper respiratory conditions. Its polyphenols (CAPE, galangin, quercetin) demonstrate antimicrobial, antiviral, and anti-inflammatory activities. Some clinical evidence supports reduction in URTI incidence and severity in children.

The EMA HMPC monograph and ESCOP recognize queen of the meadow as a traditional herbal product for colds and minor respiratory symptoms. The plant's diaphoretic action supports fever management in colds, and antitussive properties are noted in empirical medicine. No clinical trial evidence exists for respiratory outcomes specifically.

Quillaja saponaria has a long record of traditional use by Andean peoples for various chest and upper respiratory problems. The saponin-rich bark is used as an expectorant and cough remedy. Evidence remains traditional with no controlled clinical trials.

Native American traditions specifically document red root use for catarrh, sore throats, fevers, and mucous membrane problems of the upper respiratory tract. The Eclectic tradition further refined this use for pharyngeal and laryngeal complaints. No human clinical trials on upper respiratory outcomes exist.

Schizonepeta has been used for over 2,000 years in TCM for upper respiratory conditions including colds, sore throat, nasal congestion, and early respiratory infections. It is categorized as an exterior-releasing herb that supports the body's defense against respiratory pathogens. Evidence is primarily traditional and preclinical.

Siler root's dried root (Radix Saposhnikoviae) is cited in the Chinese Journal of Integrative Medicine review as a traditional Chinese herbal medicine used for respiratory diseases. Its TCM applications include suppressing cough, relieving nasal symptoms, and clearing early-stage respiratory pathogens. Modern evidence is limited to preclinical anti-inflammatory and antiallergic findings.

S. baicalensis is documented in TCM for over 2,000 years for upper respiratory tract infections. Ben Cao Gang Mu lists it for 'upper respiratory tract infections.' The Iroquois used S. lateriflora root infusions for throat clearance. Clinical use in China for acute pulmonary infections continues.

Slippery elm (Ulmus rubra) inner bark is classified as a safe and effective OTC throat demulcent by the FDA. Its mucopolysaccharide mucilage coats and soothes irritated pharyngeal and upper respiratory mucosae. It has extensive traditional use among North American Indigenous peoples for coughs, sore throats, and respiratory infections.

Slippery elm bark (Ulmus rubra inner bark) is an FDA-recognized safe and effective OTC throat demulcent. Its mucilage physically coats irritated pharyngeal mucosae to soothe sore throat and cough associated with upper respiratory infections. Used for centuries in North American Indigenous medicine for respiratory conditions.

Multiple spruce species have documented traditional use across Native American and European folk medicine for upper respiratory infections, including coughs, colds, and throat complaints. The volatile oil and resin provide antiseptic, expectorant, and mucolytic actions in the upper airways. Registered European herbal medicines use Norway spruce for this indication.

Stillingia was used in Native American medicine and by Eclectic physicians to support the upper respiratory system, including the throat, larynx, and airways. Root chewing and tinctures were employed during winter months for this purpose. No clinical data exist.

Tartarian aster root is one of TCM's primary herbs for upper respiratory conditions, used for over 2,000 years for coughs, colds, and bronchial infections. It is listed in the Chinese Pharmacopoeia as an expectorant and antitussive. Preclinical data support antibacterial and antiviral actions against upper respiratory pathogens. No human RCTs for upper respiratory infections as a standalone indication are available.

Tylophora is a well-established Ayurvedic and folk remedy for upper respiratory complaints including sore throat, cold, cough, and sinusitis. It has been traditionally used in Indian folk medicine for whooping cough, cold, cough, and sore throat, and is described in ethnobotanical literature as a broad respiratory tonic.

Watercress has extensive traditional documentation as an expectorant and remedy for coughs, colds, flu, and upper respiratory tract infections across European, Iranian, Moroccan, and Indian medical traditions. It was used by ancient Greek and Roman physicians and remains in documented traditional use. No specific clinical RCT for upper respiratory outcomes exists.

Beyond nasal conditions, X. strumarium has traditional TCM documentation for chronic bronchitis, and preclinical studies in asthmatic mice models show anti-inflammatory effects of xanthatin via STAT3 and NF-κB inhibition. Use for upper respiratory complaints is one of the plant's most consistent cross-cultural traditional applications.